First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers

HDIT101 is a first‐in‐class humanized monoclonal antibody recognizing a conserved epitope in glycoprotein B, a target present on the surface of herpes simplex virus 1 (HSV‐1) and HSV‐2 particles as well as on virus‐infected cells. This was a first‐in‐human, single‐center, double‐blind, placebo‐contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Blank, Antje, Hohmann, Nicolas, Dettmer, Marlen, Manka‐Stuhlik, Anette, Mikus, Gerd, Stoll, Felicitas, Stützle‐Schnetz, Marlies, Thomas, Daniel, Exner, Evelyn, Schmitt‐Bormann, Beate, Schaller, Torsten, Laage, Rico, Schönborn‐Kellenberger, Oliver, Arndt, Michaela, Haefeli, Walter E., Krauss, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579396/
https://www.ncbi.nlm.nih.gov/pubmed/35869929
http://dx.doi.org/10.1111/cts.13365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579396/
https://www.ncbi.nlm.nih.gov/pubmed/35869929
http://dx.doi.org/10.1111/cts.13365

Ejemplares similares